Literature DB >> 12606549

Tyrosine phosphorylation of the well packed ephrinB cytoplasmic beta-hairpin for reverse signaling. Structural consequences and binding properties.

Jianxing Song1.   

Abstract

Tyrosine phosphorylation of the 22-residue cytoplasmic region of ephrinB induces its binding to the SH2 domain of Grb4, thus initiating reverse signaling pathways controlling cytoskeleton assembly and remodeling. Recently, the region corresponding to this 22-residue motif was demonstrated to adopt a well packed beta-hairpin structure with a high conformational stability in the unphosphorylated cytoplasmic subdomain. However, because the binding to Grb4 is phosphorylation-dependent and the hairpin contains three conserved tyrosine residues that may be phosphorylated, the key events remain unknown as to how tyrosine phosphorylation affects the structure of this well packed beta-hairpin and which phosphorylation site is relevant to SH2 domain binding. By characterizing the structural and binding properties of six 22-residue SH2 domain-binding motifs with different phosphorylated sites, the present study reveals that, as shown by circular dichroism and NMR, the unphosphorylated 22-residue motif adopts a well formed beta-hairpin structure in isolation from the ephrinB cytoplasmic subdomain. However, this beta-hairpin is radically abolished by tyrosine phosphorylation, regardless of the relative location and number of Tyr residues. Unexpectedly, the peptides with either Tyr304 or Tyr316 phosphorylated show high affinity binding to SH2 domain, whereas the peptide with Tyr311 phosphorylated has no detectable binding. This implies that ephrinB with Tyr311 phosphorylated might have a currently unidentified binding partner distinct from the Grb4 protein, because Tyr311 is known to be phosphorylated in vivo. Based on the results above, it is thus proposed that the disruption of the tight side-chain packing by tyrosine phosphorylation in the well structured region of a signaling protein may represent a general activation mechanism by which a cryptic binding site is disclosed for new protein-protein interactions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12606549     DOI: 10.1074/jbc.M210625200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  NMR assignment of the human ephrinB2 ectodomain.

Authors:  Xiaoyuan Ran; Jing-song Fan; Jianxing Song
Journal:  J Biomol NMR       Date:  2006-10-24       Impact factor: 2.835

2.  Crystal structure and NMR binding reveal that two small molecule antagonists target the high affinity ephrin-binding channel of the EphA4 receptor.

Authors:  Haina Qin; Jiahai Shi; Roberta Noberini; Elena B Pasquale; Jianxing Song
Journal:  J Biol Chem       Date:  2008-08-14       Impact factor: 5.157

3.  ephrinB1 signals from the cell surface to the nucleus by recruitment of STAT3.

Authors:  Yong-Sik Bong; Hyun-Shik Lee; Laura Carim-Todd; Kathleen Mood; Tagvor G Nishanian; Lino Tessarollo; Ira O Daar
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-22       Impact factor: 11.205

4.  Tyr-298 in ephrinB1 is critical for an interaction with the Grb4 adaptor protein.

Authors:  Yong-Sik Bong; Yeon-Hwa Park; Hyun-Shik Lee; Kathleen Mood; Akihiko Ishimura; Ira O Daar
Journal:  Biochem J       Date:  2004-01-15       Impact factor: 3.857

5.  Protein dynamics at Eph receptor-ligand interfaces as revealed by crystallography, NMR and MD simulations.

Authors:  Haina Qin; Liangzhong Lim; Jianxing Song
Journal:  BMC Biophys       Date:  2012-01-25       Impact factor: 4.778

6.  Presenilin-dependent intramembrane cleavage of ephrin-B1.

Authors:  Taisuke Tomita; Sayaka Tanaka; Yuichi Morohashi; Takeshi Iwatsubo
Journal:  Mol Neurodegener       Date:  2006-06-12       Impact factor: 14.195

Review 7.  Why do proteins aggregate? "Intrinsically insoluble proteins" and "dark mediators" revealed by studies on "insoluble proteins" solubilized in pure water.

Authors:  Jianxing Song
Journal:  F1000Res       Date:  2013-03-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.